ClariVest Asset Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

ClariVest Asset Management’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,513	Closed	-$298K	–	820
2022 Q1	$298K	Sell	2,513 -1,883	-43%	-$235K	0.01%	439
2021 Q4	$606K	Sell	4,396 -308	-7%	-$39.2K	0.02%	407
2021 Q3	$654K	Buy	+4,704	New	+$587K	0.02%	394

Other funds holding BHVN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ClariVest Asset Management's BHVN Position: Q2 2022 in Review

ClariVest Asset Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2022, closing a stake of 2,513 shares — an estimated $298K sold.

ClariVest Asset Management first reported a position in BHVN in Q3 2021 and held it in 3 quarters. The position peaked at $654K in Q3 2021. 329 funds tracked by Wall St. Rank hold BHVN as of Q2 2022.

ClariVest Asset Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2022 after selling out during the quarter.
ClariVest Asset Management sold 2,513 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2022, an estimated $298K.
ClariVest Asset Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2021 and held it in 3 quarters.
ClariVest Asset Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $654K in Q3 2021.
329 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2022.

Based on ClariVest Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.